BioCentury
ARTICLE | Financial News

Biohaven planning $100M IPO

April 10, 2017 6:25 PM UTC

Biohaven Pharmaceutical Holding Co. Ltd. (New Haven, Conn.) filed to raise up to $100 million in an IPO on the New York Stock Exchange underwritten by Morgan Stanley, Piper Jaffray, Barclays, William Blair and Needham.

In December, Biohaven began a Phase II/III study of trigriluzole (formerly BHV-4157) to treat spinocerebellar ataxia. The candidate is a prodrug formulation of riluzole, a glutamate modulating agent. Biohaven obtained worldwide rights to trigriluzole in 2015 from ALS Biopharma LLC (Doylestown, Pa.)...